pneumococcal vaccine: clinical use

Prescribing considerations

• Confirm eligibility, previous pneumococcal vaccination, current programme vaccine, and clinical risk category.
• Consider reduced immunogenicity during or after immunosuppressive treatment.
• Vaccination does not replace antibiotic prophylaxis or urgent assessment of suspected infection in people at particularly high risk.

Contraindications and cautions

• Hypersensitivity to the active substances or any excipient.
• Defer during significant febrile illness or another active infection unless delay presents greater risk.
• The selected polysaccharide vaccine is not licensed below 2 years and produces an unreliable antibody response in this age group.
• Avoid intravascular and intradermal administration.

Monitoring

• Ensure immediate treatment for anaphylaxis is available.
• Record vaccine name and batch number.
• Advise about expected reactions and when urgent assessment is needed.

Clinical pharmacology

Purified capsular polysaccharides induce serotype-specific antibodies mainly through T-cell-independent mechanisms. Pharmacokinetic studies are not applicable.

Formulation and product differences

• The selected PPV23 product is a clear, colourless solution in a pre-filled syringe containing purified polysaccharides from 23 pneumococcal serotypes.
• Conjugate vaccines link polysaccharides to a carrier protein, improving immune responses, particularly in young children.
• The programme began moving from PPV23 to PCV20 in early 2026; PPV23 is no longer available to order through the national programme, although existing provider stock may still be used in accordance with current guidance.